***SNDY***____DD...... by Stock130....Chart @ Bott
Post# of 144482
- SNDY has ~30 FDA Approved products.
-SNDY has over 3,000+ Solos Endoscopy Systems sold throughout the U.S. market.
-They have retired 150m shares in Feb. 2012.
-Current share structure is low ~608m O/S and ~950m A/S.
-SNDY is set to release the SteriTap product line which is already approved for the CE Mark (Sale in Europe).
-SNDY reduced their debt by 688k
-SNDY reduced their debt by 570k
-Solos Endoscopy will focus on new product development.
SNDY Expectations from PR's and the Presidents Report:
-SNDY sales of the MammoView are expected to increase.
-SNDY expected to be debt free by Q2.
-Expecting additional updates regarding CE Mark for the MammoView product line (sales outside the USA).
-Confirmation of additional debt reduction.
-Confirmation of increased sales and acceptance of MammoView.
-Release of SteriTap.
-Company expects to achieve a Positive Net Book Value when it posts its second quarter financials .
-Solos Endoscopy plans on developing new strategic partnerships and joint ventures.